Microglia: A Potential Drug Target for Traumatic Axonal Injury

Xin Huang1, Wendong You2, Yuanrun Zhu2

  • 1Department of Neurosurgery, First Affiliated Hospital, Zhejiang University School of Medicine, China.

Neural Plasticity
|June 7, 2021
PubMed

Insights

Traumatic axonal injury (TAI) following brain injury is a major cause of death. Promoting M2-phenotype microglia may offer a new therapeutic strategy for TAI recovery.

Area of Science:

  • Neuroscience
  • Traumatic Brain Injury Research
  • Neuroinflammation

Background:

  • Traumatic axonal injury (TAI) is a significant cause of mortality and disability in severe traumatic brain injury (TBI).
  • Neuroinflammation, particularly microglial activation, is implicated in TAI pathogenesis.
  • Current therapeutic options for TAI remain limited.

Purpose of the Study:

  • To review current research on the role of microglial activation in TAI.
  • To explore potential therapeutic strategies targeting microglial modulation for TAI recovery.

Main Methods:

  • Literature review of recent studies on TAI and microglial activation.
  • Analysis of therapeutic approaches aimed at modulating microglial phenotype post-TBI.

Main Results:

  • Recent studies indicate a critical role for microglial activation in the development of TAI.
  • Modulating microglial phenotype shows promise for aiding TAI recovery.

Conclusions:

  • Microglial activation is a key factor in TAI development after TBI.
  • Shifting microglia towards the M2 phenotype represents a potential therapeutic target for TAI treatment.